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Abstract
Background: A substantial portion of Clostridium difficile infection (CDI) cases occur in communities, and
community-onset CDI (CO-CDI) can lead to serious complications including mortality. This study aimed to identify
the risk factors for a poor outcome in CO-CDI.
Methods: We performed a retrospective review of all inpatients with CDI, in a 1300-bed tertiary-care hospital in
Korea, from 2008 through 2015. CO-CDI was defined as CDI occurring within 48 h of admission. Poor outcome was
defined as follows: 1) all-cause 30-day mortality, 2) in-hospital mortality, or 3) surgery due to CDI.
Results: Of a total 1256 CDIs occurring over 8 years, 152 (12.1%) cases were classified as CO-CDI and 23 (15.1%) had
a poor outcome, including 22 (14.5%) cases of mortality and 2 (1.3%) cases of surgery. Patients with a poor
outcome had a higher mean age than those without a poor outcome (75.8 vs. 69.6 years, p = 0.03). The proportion
of men and prior proton pump inhibitor (PPI) use were significantly higher in the poor outcome group (65.2% vs.
41.9%, p = 0.04; 39.1% vs. 17.6%, p = 0.02, respectively). Multivariate binary logistic model showed that PPI use and
anemia (hemoglobin < 10 g/dL) at presentation were significantly associated with a poor outcome (adjusted odds
ratio [aOR], 3.76; 95% confidence interval [95CI], 1.26–11.21, aOR, 4.67; 95CI, 1.52–14.34, respectively).
Conclusions: Clinicians should not only be aware of the possibility of CDI in the community setting but also pay
more attention to PPI-using elderly patients with anemia in consideration of a poor outcome.
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Background
Clostridium difficile is an anaerobic spore-forming bac-
terium that is resistant to gastric acid; thus, it can stay in
the intestinal tract and proliferate when the normal gut
flora is disrupted under specific circumstances such as
antibiotic agent usage. C. difficile infection (CDI) has
been identified as a major cause of nosocomial diarrhea.
CDI can show various manifestations, from mild
diarrhea to severe colitis or toxic megacolon, which can
result in surgery or even mortality.
The incidence of CDI has been increasing over the last
10 to 20 years, and several outbreaks of CDI have oc-
curred globally [1]. In the United States, costs associated
with CDI exceed $1.1 billion per year, even with conser-
vative estimates [2]. Recent studies have reported that a
substantial portion of CDI occurs in the community and
its incidence has been increasing [3]. In a previous
report, only 24.2% of CDI occurred during hospitalization
in the United States [4]. An Australian study reported that
community-onset CDI (CO-CDI) accounted for 29% of
CDI [5]; in a Taiwanese report, CO-CDI accounted of 15%
CDI when the percentage of community-acquired CDI
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and community-onset healthcare-associated CDI were
combined [6]. Moreover, some CO-CDI resulted in poor
outcomes in those reports [5, 6].
Age over 70 years, leukocytosis, hypoalbuminemia, in-
creased creatinine, nasogastric tube feeding, and small
bowel obstruction or ileus are known risk factors for se-
vere CDI and are associated with a high mortality [7, 8].
However, some reports have revealed that patients with
CO-CDI show different characteristics compared to pa-
tients with traditional nosocomial infection [9]. It is pos-
sible that the manifestations of complicated CO-CDI
differ from those of nosocomial infection; however, few
studies have investigated the risk factors for complica-
tions in CO-CDI. Thus, this study aimed to evaluate the
clinical characteristics of CO-CDI and to identify the
risk factors for a poor outcome in CO-CDI.
Methods
Study design and definitions
We performed a retrospective medical review in Seoul
National University Bundang Hospital, which is a
1300-bed tertiary-care hospital located in Seongnam,
Gyeonggi-do, South Korea. A medical record review was
performed for all adults (≥ 18 years old) admitted from
2008 to 2015.
CDI was defined as a positive C. difficile toxin test and
diarrhea or an equivocal C. difficile toxin test, diarrhea,
and treatment for CDI. Diarrhea was defined as de-
scribed in the medical records or as defecation exceed-
ing 3 times in a day. ELISA was used to identify C.
difficile toxin A or B (Gemini analyser, Stratec Biomed-
ical GmbH, Birkenfeld, Germany), performed as per the
manufacturer’s instructions in a single microbiology la-
boratory. CO-CDI was defined as CDI occurring within
48 h of admission. We regarded patients who were re-
currently admitted multiple times within 1 week as one
episode on the first admission day. When CDI occurred
more than two times during one admission, we regarded
the latter case as nosocomial CDI, which was excluded
from this review. Poor outcome was defined if one of
the following events occurred: 1) all-cause 30-day mor-
tality, 2) in-hospital mortality or 3) surgery due to CDI.
CDI treatment was defined as the use of intravenous/
oral metronidazole, oral vancomycin, or both.
Study measures
We collected epidemiological information such as sex,
age, admission date, medical history including cardiovas-
cular disease, diabetes mellitus, renal disease, hepatic
disease, malignancy, and previous CDI from the medical
records. A recent event of previous CDI was defined as
an event occurring within the most recent 3 months.
We reviewed recent medication histories such as
antibiotic agent and proton pump inhibitor (PPI) use for
the previous 1 month. We collected data on clinical
manifestations (vital signs such as blood pressure, body
temperature, Glasgow coma scale, stool frequency > 10
per day, presence of mucoid stool, duration of diarrhea
before admission, abdominal pain, abdominal tender-
ness, intensive care unit [ICU] admission), laboratory
values (white blood cell [WBC] count, hemoglobin, cre-
atinine, albumin, glucose), radiographic data (plain radi-
ography, computed tomography [CT]), and endoscopic
results. Duration from admission to the treatment of
CDI in days and the number of patients who needed to
continue possible offending antimicrobial agents were
reviewed. Laboratory data within 24 h from admission
were collected and values with the greatest deviations
from normal were collected if multiple values were avail-
able. In addition, medical images taken within 7 days of
the C. difficile toxin test were reviewed.
Statistical analysis
The independent Student t-test or Mann-Whitney
U-test was used to compare continuous variables be-
tween the poor and good outcome groups, depending
on the normality of data. The chi-square test was used
for categorical variables. Linear regression was used to
evaluate trends of incidence. To evaluate independent
factors for a poor outcome in CO-CDI, we designed two
logistic regression models. The first model included sig-
nificant demographic and clinical variables identified
from univariate analysis. The second model included sig-
nificant laboratory variables which were identified from
univariate analysis and are known to be associated with
severity in previous studies. We separated the variables
into two models rather than combining all of them into
one model. This was because a small study population
and a large number of variables and covariates with po-
tential collinearity might have affected the power of the
study and the statistical relevance of the results.
Two-sided tests were performed and P-values of < 0.05
were considered statistically significant. The incidence
rate was calculated for 10,000 admissions. All statistical
analyses were performed with SAS for Windows, version
9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Characteristics of the population
During the 8-year study period, a total of 1256 CDI epi-
sodes were identified. Of these, 152 were classified as
CO-CDI. Although the number of cases of CDI in-
creased annually, the number of C. difficile toxin testing
was also increased from 172 CDI cases/861 tests in 2008
to 256 CDI cases/2072 tests in 2015 (Additional file 1:
Figure S1). However, there was no significant trend in
the CDI incidence rate after the conversion 10,000
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admission rates per month (p = 0.36, overall 32.75 per
10,000 admissions per month). There was no particular
trend in the CO-CDI incidence rate (p = 0.51, overall
3.64 per 10,000 admissions per month). No significant
trend was observed in the incidence rate of complicated
CO-CDI (p = 0.84, overall 0.55 per 10,000 admissions
per month).
The mean patient age was 70.66 (SD 14.89), with a
slight female predominance (54.6%) (Additional file 1:
Table S1). There were 37 (24.3%) cases from the
long-term care facility. The mean Charlson’s comorbidity
index was 2.09 (SD 1.90) and there were 23 (15.0%)
cases with previous CDI; 119 (79.3%) cases had a history
of antibiotic agent usage within the previous 1 month.
Fifteen (9.9%) cases did not have an antibiotic or admis-
sion history for 3 months. Thirty-one (21.0%) cases had
a history of prior PPI use. There were 42 (27.6%) cases
with shock at the initial presentation. Eleven (7.2%) cases
required ICU admission.
We identified the prior use of antibiotic agents within
1 month in 110 (71.9%) cases of CO-CDI. The antibiotic
classification was ascertained in 95 (62.5%) cases. The
most frequently used antibiotic agent was cephalosporin
and it was used for 48 (50.5%) cases. Following, in the
order of frequency, are fluoroquinolone in 37 (39.0%),
β-lactam + β-lactamase inhibitor in 19 (20.0%), metro-
nidazole in 9 (9.5%), carbapenem in 8 (8.4%) cases. Clin-
damycin was used in 2 (2.1%) cases.
Risk factors for a poor outcome in CO-CDI
There were 23 (15.1%) cases with a poor outcome. Of
these, there were 22 (14.5%) cases of mortality: 19
(12.5%) during the admission period and 14 (9.2%)
within 30 days from admission. There were 2 cases of
surgery, and of these, mortality occurred during admis-
sion in one case.
The mean age of patients and the proportion of men
in the poor outcome group was higher than that in the
good outcome group (75.8 vs. 69.6 years, p = 0.01; 65.2%
vs. 41.9%, p = 0.04, respectively; Additional file 1: Table
S1). The mean heart rate within 24 h after admission
was significantly higher in the poor outcome group
(109.80 vs. 98.1 beats per min, p = 0.01); however, there
was no significant difference in the proportion of septic
shock or mean body temperature between the two
groups. The rate of prior PPI use was higher in the poor
outcome group (39.1% vs. 17.6%, p = 0.02). The rate of
prior antibiotic agent use was not significantly different
between the two groups (73.9% vs. 80.3%, p = 0.49).
When analyzed by the classification of possible offending
antibiotic agents, penicillin derivatives were more fre-
quently used in the poor outcome group (40.0% vs.
16.3%, p = 0.03; Additional file 1: Table S2). Clinical
manifestations including mucoid stool, proportion of
stool frequency exceeding 10 times, duration of symp-
toms, and abdominal pain or tenderness were not sig-
nificantly different between the two groups. Laboratory
values at presentation showed that the mean WBC
count was higher in the poor outcome group, but this
finding was not statistically significant. The mean
hemoglobin level was marginally lower in the poor out-
come group (10.42 g/dL vs. 11.30 g/dL, p = 0.06), and
the mean bicarbonate and albumin levels were signifi-
cantly lower in the poor outcome group than in the
good outcome group (19.52 mmol/L vs. 21.84 mmol/L,
p = 0.02; 2.63 g/dL vs. 3.21 g/dL, p = 0.0001,
respectively).
Multivariate binary logistic analysis revealed that a his-
tory of PPI use was independently associated with a poor
outcome (adjusted odds ratio [aOR], 3.88; 95% confi-
dence interval [95CI], 1.310–11.518). In addition, anemia
of hemoglobin under 10 g/dL was associated with a poor
outcome (aOR, 3.55; 95CI, 1.230–10.219). Men were
marginally associated with the increased risk of a poor
outcome in CO-CDI (aOR, 2.74; 95CI, 0.998–7.525;
Table 1).
Discussion
This study analyzed 152 CO-CDI episodes from a total
of 1368 CDI cases, giving the proportion of 12.1%. A
substantial proportion (15.1%) of CO-CDI cases under-
went surgery and/or expired. Prior PPI use and anemia
under hemoglobin 10 g/dL were associated poor out-
comes in multivariate analyses.
The prevalence of CO-CDI has been reported to range
between 10 and 42% in various countries [5, 6, 10]. We
observed that CO-CDI comprised 12.1% of CDI and this
result is comparable with these previous studies. In this
study, in-hospital mortality and 30-day mortality were
12.5 and 9.2%, respectively. These rates are similar to
findings in previous CO-CDI reports and are also com-
parable with the mortality in nosocomial CDI [6]. The
factors associated with a poor outcome in CO-CDI were
similar to those noted in previous studies in the univari-
ate analysis but were slightly different in the multivariate
analysis. Male sex and old age, similar to that in our
study, have been identified as predictive risk factors for
severe CDI in previous reports [7]. Elderly patients over
70 years comprised 62.5% of CO-CDI patients in our
study. We confirmed that CO-CDI occurred more in the
elderly and that they are more prone to have a poor out-
come. In agreement with a previous report by Khanna et
al. [10] which showed that CO-CDI in relatively young
patients may follow a milder clinical course, we demon-
strated that older patients with CO-CDI still had a
higher risk of a poor outcome.
To the best of our knowledge, no previous report has
attempted to clarify the risk factors for severe outcomes
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in CO-CDI. This study demonstrated that PPI use is as-
sociated with a poor outcome in CO-CDI, similar to that
in nosocomial CDI. PPI is known to be associated with
the development [9, 11], severity [12], and recurrence
[8] of CDI, and has recently been reported to be associ-
ated with the development of CO-CDI [13]. In a phar-
macoepidemiologic cohort study, Howell et al. [14]
reported that iatrogenic gastric acid suppression in-
creases CDI development with a dose-response effect,
suggesting a causal relationship. In an in vitro study,
Jump et al. [15] reported the prolonged survival of C.
difficile in the gastric contents of PPI-using patients with
elevated pH (pH > 5). Another study reported that
exposure to PPI promoted toxin gene expression of C.
difficile [16]. Furthermore, an experimental study with
mice demonstrated that toxin A and B titers and myelo-
peroxidase activity, which is a marker for inflammatory
activity was elevated in both antibiotic and proton pump
inhibitor-receiving groups [17]. This finding suggests
that PPIs should be appropriately used.
Anemia reflects the general condition of a patient,
such as nutritional status (e.g. iron, vitamin deficiency),
as well as underlying chronic diseases. However, we
could not find any previous report regarding a direct as-
sociation of anemia with human CDI. In a study, an as-
sociation between anemia and colitis was noted in a
mouse acute colitis model [18]. Anemia is also influ-
enced by the pro-inflammatory cytokine-mediated inhib-
ition of erythropoiesis [19]. It is possible that anemia in
patients at the initial presentation of CDI might repre-
sent the severity of CDI associated with relative ischemia
in an inflammatory condition of the colon. Thus, we
thought that anemia could be a significant factor for
poor outcomes in CO-CDI, as a representative of an
underlying condition and severity of acute illness.
Regarding possible offending antibiotic agents,
cephalosporin was used most frequently, followed by
fluoroquinolone, and β-lactam + β-lactamase inhibitor
in a descending order. Conventionally, clindamycin is a
known risk factor for nosocomial CDI and CO-CDI [20].
In this report, only 2 patients were administered clindamy-
cin before admission. One reason for this is that clinicians
may have avoided prescribing clindamycin because of the
associated risk of CDI. Additionally, broad-spectrum antibi-
otics such as β-lactam + β-lactamase inhibitor or carba-
penem are being used increasingly, decreasing the need for
extra anaerobic bacterial coverage [21]. Except for clinda-
mycin, three dominant antibiotic classes in this study were
noted among previously reported drugs associated with
CO-CDI risk in a meta-analysis [22].
This study has some limitations. The first limitation of
this study includes its single-center retrospective study
design. Cases of CDI could have been missed if primary
physicians did not suspect CDI and did not test for the
C. difficile toxin in patients from the community with
relatively mild diarrhea, who did not have a history of
antibiotic use. Thus, the CDI prevalence rate could have
been underestimated. This assumption might explain the
older age and higher proportion of febrile patients in
this study compared to a previous community-based
study [23]. However, we believe that our study included
sufficient cases of severe CO-CDI and is valuable in this
Table 1 Risk factors for poor outcome in community-onset Clostridium difficile infection in multivariate logistic regression analyses
Variable Odds ratio 95% CI P
Age > 70 y 1.47 0.468–4.627 0.51
Male 2.74 0.998–7.525 0.05
Long-term care facility residence 0.98 0.287–3.354 0.98
Glasgow coma scale ≤12 2.06 0.589–7.185 0.26
Presentation with septic shock 0.84 0.256–2.742 0.77
Heart rate≥ 100 /min 2.81 0.972–8.102 0.06
Prior proton pump inhibitor use within 1 month 3.88 1.310–11.518 0.01
ICU admission 2.71 0.599–12.257 0.20
Max leukocyte count > 20,000 /mL 2.78 0.897–8.684 0.08
Min hemoglobin level < 10 g/dL 3.55 1.230–10.219 0.02
Min bicarbonate level < 20 mmol/L 2.16 0.736–6.356 0.16
Max glucose level > 150 mg/dL 0.83 0.259–2.623 0.74
Max creatinine level > 2 mg/dL 0.54 0.160–1.841 0.33
Min albumin level < 2.5 g/dL 1.21 0.373–3.928 0.75
ICU Intensive care unit, Max maximum, Min Minimum, CI, confidence interval
Poor outcome was defined if at least one of following event was occurred: 1) all-cause 30-day mortality, 2) in-hospital mortality, or 3) surgery due to C.
difficile infection
Clinical variables (n-152) and laboratory variables (n = 151) were analyzed in two separated models in consideration of potential collinearity
Laboratory results were the most deviated value from normal range within 24 h after admission
Lee et al. Antimicrobial Resistance and Infection Control  (2018) 7:75 Page 4 of 6
regard. Second, we did not investigate whether micro-
biological characteristics (e.g., ribotype) are associated
with complicated CO-CDI. In a nationwide study from
12 hospitals in Korea, a major strain of nosocomial CDI
was ribotype 017 [24]. There was limited data on the C.
difficile strain in the case of CO-CDI in Korea, and we
did not find any report on the relationship between ribo-
type and severity. Although the hypervirulent strain of
ribotype 027 was described for the first time in Korea in
2009 [25], it does not appear to be epidemic or endemic
in Korea yet. Considering previous reports on the preva-
lence rate in Korea, it does not appear to be an epidemic
of a hypervirulent strain based on the prevalence rate
compared to a previous study in Korea [26].
Conclusions
In this study, a substantial proportion of CDI occurred
in the community. Clinicians should suspect CO-CDI in
patients with diarrhea, abdominal pain, abdominal ten-
derness, and fever, who have a history of antibiotic use.
In particular, patients with anemia at presentation and
who use PPI need additional attention considering the
identification of anemia and PPI use as risk factors for a
poor outcome.
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